quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 18, 2026

JPMorgan has stark message on Qualcomm stock

View original at finance.yahoo.com
JPMorgan has stark message on Qualcomm stock JPMorgan is becoming more cautious on QUALCOMM Incorporated (QCOM) ahead of its upcoming earnings report, citing rising pressure in its core handset business…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • QCT revenue expected to decline 22% in calendar 2026

    60% confidence

  • Qualcomm's stock may not be cheap relative to normalized earnings power if handset weakness persists

    60% confidence

  • QCT EBT margin guidance of 26-28% for fiscal Q2 2026, down from 31% previously

    60% confidence

  • Fiscal Q2 2026 non-GAAP EPS guidance of $2.45 to $2.65

    60% confidence

  • Fiscal Q2 2026 revenue guidance of $10.2 billion to $11.0 billion

    60% confidence

  • Rising pressure in Qualcomm's core handset business with newer growth areas not yet large enough to offset weakness

    60% confidence

  • Meaningful near-term downside risk with no clear event likely to improve the outlook for Qualcomm

    60% confidence

Data points we hold from this source

Qualcomm Incorporated · price target140 USD
Qualcomm Incorporated · previous price target185 USD
Qualcomm Incorporated · eps guidance low2.45 USD
Qualcomm Incorporated · eps guidance high2.65 USD
Qualcomm Incorporated · eps3.50 USD
Qualcomm Incorporated · revenue guidance high11.0 USD
Qualcomm Incorporated · revenue guidance low10.2 USD
Qualcomm Incorporated · consensus revenue12.21 USD
Qualcomm Incorporated · consensus eps3.39 USD

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
JPMorgan has stark message on Qualcomm stock — Source | Via News | pt.VIA.NEWS